Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26985860 | 1.00 | SLC10A2 (0.39) | SLC10A2ALDH1A1 | |
| SCHEMBL26986038 | 1.00 | SLC10A2 (0.39) | SLC10A2ALDH1A1 | |
| SCHEMBL26986007 | 1.00 | SLC10A2 (0.39) | SLC10A2ALDH1A1 | |
| SCHEMBL30728346 | 1.00 | SLC10A2 (0.39) | SLC10A2ALDH1A1 | |
| SCHEMBL30728138 | 1.00 | SLC10A2 (0.39) | SLC10A2ALDH1A1 | |
| SCHEMBL26986233 | 0.97 | SLC10A2 (0.39) | SLC10A2ALDH1A1 | |
| SCHEMBL30728249 | 0.97 | SLC10A2 (0.39) | SLC10A2ALDH1A1 | |
| SCHEMBL26990277 | 0.95 | SLC10A2 (0.39) | SLC10A2 | |
| SCHEMBL30728111 | 0.93 | SLC10A2 (0.43) | SLC10A2 | |
| SCHEMBL30728141 | 0.93 | SLC10A2 (0.43) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551562-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | Albireo AB (SE) | 2025-05-14 | — | — | EP | claimed |
| WO-2024008766-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2024-01-11 | — | — | WO | claimed |
| EP-4551562-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | Albireo AB (SE) | 2025-05-14 | — | — | EP | disclosed |
| CN-119487013-A | Benzothiepine (di) nitrogen cycloheptatriene compounds Compounds and their use as bile acid modulators | 阿尔比里奥公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240067617-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2024-02-29 | — | — | US | disclosed |
| WO-2024008766-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2024-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067617-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885ALDH1A1 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.